Suppr超能文献

整合素靶向癌症免疫疗法引发保护性适应性免疫反应。

Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses.

作者信息

Kwan Byron H, Zhu Eric F, Tzeng Alice, Sugito Harun R, Eltahir Ahmed A, Ma Botong, Delaney Mary K, Murphy Patrick A, Kauke Monique J, Angelini Alessandro, Momin Noor, Mehta Naveen K, Maragh Alecia M, Hynes Richard O, Dranoff Glenn, Cochran Jennifer R, Wittrup K Dane

机构信息

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.

出版信息

J Exp Med. 2017 Jun 5;214(6):1679-1690. doi: 10.1084/jem.20160831. Epub 2017 May 4.

Abstract

Certain RGD-binding integrins are required for cell adhesion, migration, and proliferation and are overexpressed in most tumors, making them attractive therapeutic targets. However, multiple integrin antagonist drug candidates have failed to show efficacy in cancer clinical trials. In this work, we instead exploit these integrins as a target for antibody Fc effector functions in the context of cancer immunotherapy. By combining administration of an engineered mouse serum albumin/IL-2 fusion with an Fc fusion to an integrin-binding peptide (2.5F-Fc), significant survival improvements are achieved in three syngeneic mouse tumor models, including complete responses with protective immunity. Functional integrin antagonism does not contribute significantly to efficacy; rather, this therapy recruits both an innate and adaptive immune response, as deficiencies in either arm result in reduced tumor control. Administration of this integrin-targeted immunotherapy together with an anti-PD-1 antibody further improves responses and predominantly results in cures. Overall, this well-tolerated therapy achieves tumor specificity by redirecting inflammation to a functional target fundamental to tumorigenic processes but expressed at significantly lower levels in healthy tissues, and it shows promise for translation.

摘要

某些RGD结合整合素是细胞黏附、迁移和增殖所必需的,且在大多数肿瘤中过度表达,这使其成为有吸引力的治疗靶点。然而,多种整合素拮抗剂候选药物在癌症临床试验中未能显示出疗效。在这项研究中,我们转而将这些整合素作为癌症免疫治疗背景下抗体Fc效应功能的靶点。通过将工程化小鼠血清白蛋白/IL-2融合蛋白与整合素结合肽的Fc融合蛋白(2.5F-Fc)联合给药,在三种同基因小鼠肿瘤模型中实现了显著的生存期改善,包括产生具有保护性免疫的完全缓解。功能性整合素拮抗作用对疗效的贡献不大;相反,这种疗法募集了先天性和适应性免疫反应,因为任何一方的缺陷都会导致肿瘤控制能力下降。将这种整合素靶向免疫疗法与抗PD-1抗体联合使用可进一步改善反应,并主要导致治愈。总体而言,这种耐受性良好的疗法通过将炎症重定向到肿瘤发生过程的一个功能性靶点来实现肿瘤特异性,该靶点在健康组织中的表达水平显著较低,并且显示出转化应用的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d80e/5460993/d24a4b069158/JEM_20160831_Fig1.jpg

相似文献

1
Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses.
J Exp Med. 2017 Jun 5;214(6):1679-1690. doi: 10.1084/jem.20160831. Epub 2017 May 4.
2
Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Cancer Sci. 2015 Feb;106(2):134-42. doi: 10.1111/cas.12584. Epub 2015 Jan 16.
6
Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer.
Clin Cancer Res. 2008 Jan 15;14(2):579-88. doi: 10.1158/1078-0432.CCR-07-0940.

引用本文的文献

1
Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade.
Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):955-969. doi: 10.1007/s00259-024-06962-w. Epub 2024 Oct 30.
5
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.
Front Immunol. 2023 Jul 25;14:1085893. doi: 10.3389/fimmu.2023.1085893. eCollection 2023.
6
A Novel Defined Necroptosis-Related Genes Prognostic Signature for Predicting Prognosis and Treatment of Osteosarcoma.
Biochem Genet. 2024 Apr;62(2):831-852. doi: 10.1007/s10528-023-10446-1. Epub 2023 Jul 17.
7
Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors.
J Immunol. 2023 Jul 15;211(2):295-305. doi: 10.4049/jimmunol.2200950.
8
Intratumorally anchored cytokine therapy.
Expert Opin Drug Deliv. 2022 Jun;19(6):725-732. doi: 10.1080/17425247.2022.2084070. Epub 2022 Jun 2.
9
Maximizing response to intratumoral immunotherapy in mice by tuning local retention.
Nat Commun. 2022 Jan 10;13(1):109. doi: 10.1038/s41467-021-27390-6.

本文引用的文献

3
Macrophages and therapeutic resistance in cancer.
Cancer Cell. 2015 Apr 13;27(4):462-72. doi: 10.1016/j.ccell.2015.02.015. Epub 2015 Apr 6.
4
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6.
5
Tumor angiogenesis in the absence of fibronectin or its cognate integrin receptors.
PLoS One. 2015 Mar 25;10(3):e0120872. doi: 10.1371/journal.pone.0120872. eCollection 2015.
6
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3320-5. doi: 10.1073/pnas.1416159112. Epub 2015 Mar 2.
8
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.
9
Rational combinations of immunotherapeutics that target discrete pathways.
J Immunother Cancer. 2013 Sep 23;1:16. doi: 10.1186/2051-1426-1-16. eCollection 2013.
10
Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
J Med Chem. 2014 Aug 14;57(15):6301-15. doi: 10.1021/jm5000547. Epub 2014 Mar 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验